Upstream Biosciences Inc. Appoints Dr. Michael Hayden Killam Professor of Medical Genetics and the Canada Research Chair in Human Genetics to Its Scientific Advisory Board

VANCOUVER, BC--(Marketwire - October 01, 2008) - Upstream Biosciences Inc. (OTCBB: UPBS) today announced the appointment of Dr. Michael Hayden, MD, PhD, FRCPC to its Scientific Advisory Board (SAB). Dr. Hayden has co-founded three companies: Xenon Pharmaceuticals, Aspreva Pharmaceuticals Inc., and Neurovir. He is currently serving as chief scientific officer for Xenon and chairman of the medical advisory board for Aspreva. Aspreva focuses on repurposing existing drugs to treat rare diseases and was purchased in a deal worth approximately $915 million US by the Galenica Group. Dr. Hayden is a full professor of Medical Genetics at the University of British Columbia as well as Director of the Center for Molecular Medicine and Therapeutics (CMMT) in Vancouver; the CMMT is a gene research center under UBC's Faculty of Medicine.

Back to news